Kalvista Pharmaceuticals (NASDAQ:KALV) Rating Increased to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a hold rating to a buy rating in a research note issued to investors on Wednesday, Zacks.com reports. Zacks Investment Research currently has $20.00 price target on the specialty pharmaceutical company’s stock.
According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. “
Other analysts have also recently issued research reports about the stock. Needham & Company LLC raised their target price on shares of Zuora from $27.00 to $30.00 and gave the stock a strong-buy rating in a research note on Wednesday, March 20th. Roth Capital reiterated a buy rating on shares of Kalvista Pharmaceuticals in a research note on Tuesday, May 28th. ValuEngine cut shares of Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Finally, BidaskClub cut shares of Vertex Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $29.40.
In other Kalvista Pharmaceuticals news, CEO Thomas Andrew Crockett sold 10,000 shares of Kalvista Pharmaceuticals stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $24.80, for a total value of $248,000.00. Following the completion of the sale, the chief executive officer now owns 258,810 shares in the company, valued at approximately $6,418,488. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Benjamin L. Palleiko sold 1,073 shares of Kalvista Pharmaceuticals stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $25.51, for a total transaction of $27,372.23. Following the completion of the sale, the chief financial officer now owns 33,573 shares of the company’s stock, valued at approximately $856,447.23. The disclosure for this sale can be found here. Insiders sold a total of 25,501 shares of company stock valued at $645,553 in the last quarter. Corporate insiders own 38.40% of the company’s stock.
A number of institutional investors have recently modified their holdings of KALV. FMR LLC purchased a new stake in Kalvista Pharmaceuticals in the first quarter valued at approximately $21,036,000. Marshall Wace North America L.P. purchased a new stake in Kalvista Pharmaceuticals in the first quarter valued at approximately $175,000. Marshall Wace LLP purchased a new stake in Kalvista Pharmaceuticals in the first quarter valued at approximately $843,000. Laurion Capital Management LP raised its stake in Kalvista Pharmaceuticals by 94.9% in the first quarter. Laurion Capital Management LP now owns 58,871 shares of the specialty pharmaceutical company’s stock valued at $1,685,000 after purchasing an additional 28,670 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in Kalvista Pharmaceuticals by 28.5% in the first quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock valued at $166,000 after purchasing an additional 1,292 shares in the last quarter. Institutional investors and hedge funds own 80.64% of the company’s stock.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Recommended Story: How to Invest in a Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.